Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential
File(s)
Accepted version
Author(s)
Brandts, Julia
Ray, Kausik K
Type
Journal Article
Abstract
Introduction
The lowering of low-density lipoprotein cholesterol (LDL-C), regardless of the method used, results in a reduction of cardiovascular events. Bempedoic acid is a new and until now, the only approved adenosine triphosphate citrate lyase inhibitor that works through the cholesterol-synthesis pathway (similar to statins) that leads to a safe and effective reduction in LDL-C.
Areas covered
We review clinical phase 2 and 3 studies on bempedoic acid’s lipid-lowering effect and approved indications.
Expert opinion
In the United States, bempedoic acid is currently approved for use in secondary prevention. In primary prevention, its approval is limited to individuals with heterozygous familial hypercholesterolemia (FH). However, its tolerability and safety profile may warrant its use in primary prevention besides FH. Even though its efficacy appears weaker than high-intensity statins, it may be a useful adjunct in individuals who achieve less than desirable LDL-C reductions with statins or who cannot tolerate statins, where bempedoic acid alone or in combination with ezetimibe may be useful alternatives.
The lowering of low-density lipoprotein cholesterol (LDL-C), regardless of the method used, results in a reduction of cardiovascular events. Bempedoic acid is a new and until now, the only approved adenosine triphosphate citrate lyase inhibitor that works through the cholesterol-synthesis pathway (similar to statins) that leads to a safe and effective reduction in LDL-C.
Areas covered
We review clinical phase 2 and 3 studies on bempedoic acid’s lipid-lowering effect and approved indications.
Expert opinion
In the United States, bempedoic acid is currently approved for use in secondary prevention. In primary prevention, its approval is limited to individuals with heterozygous familial hypercholesterolemia (FH). However, its tolerability and safety profile may warrant its use in primary prevention besides FH. Even though its efficacy appears weaker than high-intensity statins, it may be a useful adjunct in individuals who achieve less than desirable LDL-C reductions with statins or who cannot tolerate statins, where bempedoic acid alone or in combination with ezetimibe may be useful alternatives.
Date Issued
2020-06-21
Date Acceptance
2020-06-02
Citation
Expert Opinion on Investigational Drugs, 2020, 29 (8), pp.763-770
ISSN
1354-3784
Publisher
Taylor and Francis
Start Page
763
End Page
770
Journal / Book Title
Expert Opinion on Investigational Drugs
Volume
29
Issue
8
Copyright Statement
© 2020 Informa UK Limited, trading as Taylor & Francis Group. This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Investigational Drugs on 21 Jun 2020, available online: https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1778668
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000546493200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
ACL inhibitor
atherosclerosis
bempedoic acid
cardiovascular disease
dyslipidemia
LDL-Cholesterol
DENSITY-LIPOPROTEIN-CHOLESTEROL
ACTIVATED PROTEIN-KINASE
FAMILIAL HYPERCHOLESTEROLEMIA
EFFICACY
ETC-1002
SAFETY
Publication Status
Published
Date Publish Online
2020-06-21